Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany

Share this

Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany


  • Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1  
  • Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed between them in 2019 
  • Tyruko is an anti-α4 integrin mAb indicated as a single disease-modifying therapy (DMT) for treating adults with highly active RRMS 

Ref: Sandoz | Image: Sandoz

Related News:- Sandoz’ Tyruko (biosimilar, natalizumab) Receives the US FDA’s Approval as First Biosimilar for Relapsing Forms of Multiple Sclerosis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions